Navigation Links
Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
Date:11/1/2007

LONDON, Nov. 1 /PRNewswire/ -- Chiltern, a leading global clinical research organization, is pleased to announce that Diana Hatsis, R.N., B.S.N., C.O.T. will lecture at the JCAHPO annual continuing education program. Diana who designed an ophthalmic surgical instrument, the Hatsis LASIK Irrigation Cannula, worked in ophthalmic practice for several years prior to joining Chiltern as a Clinical Research Associate (CRA). The meeting will take place in New Orleans, Louisiana from November 9 - 13, 2007. The JCAHPO meetings will be located at the Hilton Riverside. Diana will be the lead instructor on three lectures, and co-instructing one of them with her brother, Dr. Alexander Hatsis, M.D., F.A.C.S. Dr. Hatsis was the first surgeon to perform refractive surgery with the Excimer laser on Long Island in 1995.

Monday, Nov. 12 from 11:30 am to 12:25 pm - Session 07M04

Wearing Many Hats: Managing Clinical Trials in an Ophthalmic Private

Practice

Tuesday, Nov, 13 from 10:20 am to 11:15 am - Session 04TU3

LASIK Complications (Lead Instructor: A. Hatsis, MD)

Tuesday, Nov, 13 from 11:30 am to 12:25 pm - Session 04TU4

Sands of the Sahara: A Refractive Emergency (co-instructor A. Hatsis, MD)

Tuesday, Nov, 13 from 1:50 pm to 2:45 pm - Session 07M06

Basic Surgical Assisting

"This will be my eighth year presenting at JCAHPO during AAO's annual meeting, it is always a great honor to be invited and a pleasure to teach and provide continuing education for health professionals in the field of ophthalmology," said Diana Hatsis. "My background in ophthalmology, eye surgeries, working in a private practice and now clinical research allows me to deliver courses with an insight in various aspects of the profession," Diana added.

"One of Chiltern's therapeutic expertise is ophthalmology and we have completed numerous trials, in various indications, in this area. Diana's expertise in the field of ophthalmology is well established and her passion about sharing her knowledge with others is reflected in the number of speaking engagements she has given over the years," said Kathy Zimmermann, Chiltern's Executive Director, Clinical Monitoring, Americas.

About Chiltern:

Established in 1982, Chiltern is a leading global contract research organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1100 people with 20 offices across the United States, United Kingdom, Germany, France, Italy, Spain, Poland, Czech Republic, Ukraine, India and South Africa. Chiltern provides services including Phase I and laboratory support, Global Clinical Development, Staff Resourcing, Biometrics, Regulatory and Medical Affairs.

For more information contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022

Email: Catherine.Lemercier@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bill to Ban Abortion In Indiana Introduced
2. Prince Harry Launches AIDS Charity In Memory Of Princess Diana
3. Over 300 Ill After Eating at Olive Garden, Indianapolis
4. Many Indiana Citizens Do Not Possess Health Insurance Coverage
5. Diana Could Have Been Saved Had She Been Rushed to Hospital
6. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
7. Researchers Present Ways To Reduce The Risk Of Dementia
8. Researchers Present Data Regarding The Efficiency Of Herbs
9. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
10. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
11. Drug Reactions First Present Themselves In The Mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Iowa (PRWEB) , ... April 26, 2017 , ... ... DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how ... and help farmers produce more and better food, with fewer resources. It highlights ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces Mirroring360 Pro . This new addition to the Mirroring360 product family ... education and business. , Mirroring360 Pro enables educators, business professionals and individuals to ...
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites ... defects research related to Zika virus during pregnancy, as well as other prenatal ... important science. , The Teratology Society is an international and ...
(Date:4/25/2017)... Ariz. (PRWEB) , ... April 25, 2017 , ... Emergency ... latest book of the Outlier Leadership Series, Outliers in Writing, set to publish in ... Professor of Emergency Medicine at the University of Arizona College of Medicine. He also ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, the ... announced the addition of a major new product ... Plate Seeding,). The VIPS has been developed for ... well microplates as part of the process to ... a simple and more reliable solution when compared ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: